Atypical antipsychotics as a possible treatment option for irritable bowel syndrome

Expert Opinion on Investigational Drugs

Volumn 22, Issue 5, 2013, Pages 565-572

  Pae, Chi Un ^a,b   Lee, Soo Jung ^a   Han, Changsu ^c   Patkar, Ashwin A ^b   Masand, Prakash S ^d  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Korea University College of Medicine   (South Korea)

^d Global Medical Education Inc   (United States)

Author keywords

Anxiety; Atypical antipsychotic; Depression; Irritable bowel syndrome; Neurotransmitter

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE PLUS OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

ANXIETY DISORDER; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IRRITABLE COLON; MOOD DISORDER; PAIN; PHARMACODYNAMICS; REVIEW; SLEEP DISORDER; TREATMENT DURATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 84876255797     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.782392     Document Type: Review

References (58)

1. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136-46
2. Chang FY, Chen PH, Wu TC, et al. Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac J Clin Nutr 2012;21:594-600
3. Park DW, Lee OY, Shim SG, et al. The Differences in Prevalence and Sociodemographic Characteristics of Irritable Bowel Syndrome According to Rome II and Rome III. J Neurogastroenterol Motil 2010;16:186-93
4. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992;304:87-90
5. Drossman DA, Sandler RS, McKee DC, et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982;83:529-34
6. Pae CU, Masand PS, Ajwani N, et al. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract 2007;61:1708-18
7. Masand PS, Kaplan DS, Gupta S, et al. Irritable bowel syndrome and dysthymia. Is there a relationship? Psychosomatics 1997;38:63-9
8. Viera AJ, Hoag S, Shaughnessy J. Management of irritable bowel syndrome. Am Fam Physician 2002;66:1867-74
9. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-78
10. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17
11. Graham L. ACG releases recommendations on the management of irritable bowel syndrome. Am Fam Physician 2009;79:1108-17
12. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011;25:109-27
13. Pae CU, Sohi MS, Seo HJ, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1165-73
14. Singh P, Agnihotri A, Pathak MK, et al. Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center. J Neurogastroenterol Motil 2012;18:324-31
15. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007;8:1211-19
16. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002;36:839-51
17. Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs 2013;22(3):329-39
18. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425-32
19. Weizman T, Pick CG, Backer MM, et al. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol 2003;478:155-9
20. Schreiber S, Getslev V, Backer MM, et al. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 1999;64:75-80
21. Fishbain DA, Cutler RB, Lewis J, et al. Do the second-generation "atypical neuroleptics" have analgesic properties? A structured evidence-based review. Pain Med 2004;5:359-65
22. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2008(4):CD004844
23. Dome P, Teleki Z, Kotanyi R. Paralytic ileus associated with combined atypical antipsychotic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:557-60
24. Zuccato E, Bertolo C, Salomoni M, et al. The effects of S(-) and R(+) sulpiride, metoclopramide, cisapride and domperidone on the small intestine suggest DA2-receptors are involved in the control of small intestinal transit time in rats. Pharmacol Res 1992;26:179-85
25. Niddam DM, Tsai SY, Lu CL, et al. Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: preliminary findings using magnetic resonance spectroscopy. Am J Gastroenterol 2011;106:1503-11
26. Tascedda F, Lovati E, Blom JM, et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 1999;21:211-17
27. Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130:304-11
28. Sugino H, Futamura T, Mitsumoto Y, et al. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:303-7
29. Altschuler EL, Kast RE. Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses 2005;65:65-7
30. Yu YB, Zuo XL, Zhao QJ, et al. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 2012;61:685-94
31. Nandra KS, Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatr Danub 2012;24(Suppl 1):S95-9
32. Severance EG, Alaedini A, Yang S, et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr Res 2012;138:48-53
33. Makikyro T, Karvonen JT, Hakko H, et al. Comorbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28 year follow-up of the 1966 northern Finland general population birth cohort. Public Health 1998;112:221-8
34. Lapierre L, Undeland P, Cox LJ. Lithium chloride-sodium propionate agar for the enumeration of bifidobacteria in fermented dairy products. J Dairy Sci 1992;75:1192-6
35. Basta-Kaim A, Budziszewska B, Leskiewicz M, et al. Hyperactivity of the hypothalamus-pituitary-adrenal axis in lipopolysaccharide-induced neurodevelopmental model of schizophrenia in rats: effects of antipsychotic drugs. Eur J Pharmacol 2011;650:586-95
36. Cohrs S, Roher C, Jordan W, et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 2006;185:11-18
37. Grover M, Dorn SD, Weinland SR, et al. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci 2009;54:1284-91
38. Martin-Blanco A, Pascual JC, Soler J, et al. Quetiapine in the treatment of refractory irritable bowel syndrome: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:715-16
39. Smith NL. Serotonin mechanisms in pain and functional syndromes: management implications in comorbid fibromyalgia, headache, and irritable bowl syndrome -case study and discussion. J Pain Palliat Care Pharmacother 2004;18:31-45
40. NCT00617396. Available from: http://www. clinicaltrials. gov/ct2/show/NCT00617396?term=irritable+bowel +syndrome%2Cantipsychotic& rank=2 [Last accessed 15 January 2013]
41. Marks DM, Han C, Krulewicz S, et al. History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. Prim Care Companion J Clin Psychiatry 2008;10:368-75
42. Han C, Masand PS, Krulewicz S, et al. Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. J Clin Pharm Ther 2009;34:79-88
43. Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs 2012;26:135-53
44. Potvin S, Morin M, Cloutier C, et al. Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol 2012;32:684-7
45. Stein DJ, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol 2011;26:614-28
46. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010(12):CD008120
47. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004;174:421-9
48. Gimenez S, Clos S, Romero S, et al. Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacology (Berl) 2007;190:507-16
49. Cohrs S, Meier A, Neumann AC, et al. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry 2005;66:989-96
50. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31
51. Clouse RE, Lustman PJ, Geisman RA, et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-16
52. Rooney KF, Sewell RD. Evaluation of selective actions of dopamine D-1 and D-2 receptor agonists and antagonists on opioid antinociception. Eur J Pharmacol 1989;168:329-36
53. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-709
54. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999;13(Suppl 2):15-30
55. Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992;6:273-89
56. Chen JJ, Li Z, Pan H, et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001;21:6348-61
57. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. Jama 2011;306:1359-69
58. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166(9):980-91